EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level  |
|---|
   3.4.22.43 | Atherosclerosis |
20578711 |
Solution phase synthesis of a combinatorial library of chalcones and flavones as potent cathepsin V inhibitors. |
causal interaction
therapeutic application
unassigned |
4
4
0 |
| 3.4.22.43 | Breast Neoplasms |
28424560 |
An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivors. |
causal interaction
diagnostic usage
therapeutic application
unassigned |
1
1
1
0 |
| 3.4.22.43 | Carcinoma |
32910988 |
Significance of nuclear cathepsin V in normal thyroid epithelial and carcinoma cells. |
causal interaction
diagnostic usage
ongoing research
unassigned |
3
2
3
0 |
| 3.4.22.43 | Carcinoma, Intraductal, Noninfiltrating |
31444238 |
Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ. |
causal interaction
diagnostic usage
ongoing research
unassigned |
4
3
3
0 |
| 3.4.22.43 | Colorectal Neoplasms |
32918681 |
Cathepsin V Mediates the Tazarotene-induced Gene 1-induced Reduction in Invasion in Colorectal Cancer Cells. |
causal interaction
unassigned |
1
0 |
| 3.4.22.43 | Dermatitis, Atopic |
19438477 |
The cystatin M / E-controlled pathway of skin barrier formation: expression of its key components in psoriasis and atopic dermatitis. |
causal interaction
diagnostic usage
therapeutic application
unassigned |
3
4
1
0 |
| 3.4.22.43 | Hyperhomocysteinemia |
32912629 |
HMGB1 mediates homocysteine-induced endothelial cells pyroptosis via cathepsin V-dependent pathway. |
ongoing research
unassigned |
3
0 |
| 3.4.22.43 | Lung Neoplasms |
21982919 |
Manipulating substrate and pH in zymography protocols selectively distinguishes cathepsins K, L, S, and V activity in cells and tissues. |
diagnostic usage
ongoing research
unassigned |
1
4
0 |
| 3.4.22.43 | Mucopolysaccharidoses |
33278943 |
The abnormal accumulation of heparan sulfate in patients with mucopolysaccharidosis prevents the elastolytic activity of cathepsin V. |
therapeutic application
unassigned |
1
0 |
| 3.4.22.43 | Myasthenia Gravis |
12925692 |
Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. |
causal interaction
diagnostic usage
unassigned |
3
1
0 |
